SELLAS Life Sciences (SLS) Cash from Operations Growth (1y) (2011 - 2026)
SELLAS Life Sciences (SLS) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 158.60% |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.85 Bn | - | 2.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.98% |
| Dec 31, 2025 | 31.05% |
| Sep 30, 2025 | 9.45% |
| Jun 30, 2025 | 24.29% |
| Mar 31, 2025 | 15.71% |
| Dec 31, 2024 | -48.25% |
| Sep 30, 2024 | -13.26% |
| Jun 30, 2024 | -27.97% |
| Mar 31, 2024 | 11.26% |
| Dec 31, 2023 | 6.35% |
| Sep 30, 2023 | -19.94% |
| Jun 30, 2023 | -31.33% |
| Mar 31, 2023 | -69.61% |
| Dec 31, 2022 | -3.54% |
| Sep 30, 2022 | 2.25% |
| Jun 30, 2022 | -17.62% |
| Mar 31, 2022 | 30.37% |
| Dec 31, 2021 | -245.33% |
| Sep 30, 2021 | -61.97% |
| Jun 30, 2021 | -44.87% |